Alkermes
key differentiation parameters support broad potential utility validate molecular design demonstrate anti tumor activity create dosing flexibility support broad potential utility demonstrated selective expansion of and cells demonstrated minimal changes in peripheral regulatory cells in both intravenous and subcutaneous administrations single agent activity observed with combination activity observed in combination with anti both and in hard to treat tumors plans to progress into registration enabling studies only variant in development identified based on safety and anti tumor activity achieved first objective response activity observed with in experienced patients combination activity observed with combination activity observed with multiple agents in preclinical studies may offer dosing flexibility renal cell carcinoma recommended phase dose pharmacodynamic inhibitors net | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
59 of 144
Related slides by other companies
Neumora Therapeutics
IPO
September 2023
kor antagonism has potential for broad neuropsychiatric impact potential to be first novel mechanism approved in in decades | Neumora Therapeutics
argenx SE
Investor Presentation
March 2023
musk agonist with broad potential in neuromuscular disease | argenx SE
Melrose
Investor Presentation
October 2023
potential for additional combat air support | Melrose
argenx SE
Investor Presentation
June 2023
musk agonist with broad potential in neuromuscular disease | argenx SE
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io